Imagine your body's healing process is like a construction site where too many 'demolition' proteins are destroying the building blocks before they can be used. This technology acts like a smart disposal system that identifies and removes only the specific harmful proteins causing the damage. By clearing out this biological trash, it allows the skin to finally heal and close the wound.
Diabetic foot ulcers have no approved effective treatment, leading to high amputation rates and massive healthcare costs. Current standard care is limited to basic wound management and glycemic control.
A first-in-class therapy using aptamer-based Lysosome Targeting Chimeras (LYTACs) designed to degrade IL-1β, IL-1R1, and MMP-9 proteins.
If you are a biotech drug developer dealing with the lack of approved treatments for chronic wounds — this project developed LYTACs that target IL-1β, IL-1R1, and MMP-9 to trigger protein degradation. This provides a first-in-class therapeutic mechanism to treat a condition affecting 25% of diabetes patients.
If you are a wound care manufacturer dealing with high recurrence rates of 65% in diabetic ulcers — this project developed a scalable, off-the-shelf therapy. This could be integrated into advanced dressings to provide active protein degradation at the wound site.
If you are a clinic network dealing with the high cost of DFU treatment exceeding 150Bn euros per year in Europe — this project developed a targeted therapy to reduce amputations. This helps lower the 60% amputation rate seen in severe cases.
Based on available project data, specific pricing is not provided, but the technology is described as a cost-effective, off-the-shelf, and scalable solution.
Yes, the project description explicitly states that the technology is designed to be scalable and ready-to-use.
Based on available project data, the project is in the proof-of-concept stage; specific patent or licensing terms are not listed in the summary.
The project runs from 2022-12-01 to 2027-11-30, focusing on obtaining in vivo proof-of-concept before moving toward clinical trials.
It is designed to address the unmet clinical need where current treatments are limited to surgical debridement, dressings, and glycemic control.
The consortium is lean and highly specialized, consisting of 6 partners across 4 countries (BE, ES, PT, UK). It features a strong translation focus with a 33% industry ratio, including 2 SMEs and 2 universities, led by Lincbiotech (an SME). This structure suggests a direct path from academic research to commercial application.
Contact LINCBIOTECH SOCIEDAD LIMITADA in Spain
Contact us to explore licensing opportunities for LYTAC protein degradation technology.
